Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 28, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Clinical Milestone for the Advancement of JNJ-4178 in Phase 2B Development for Chronic HCV

NEW HAVEN, Conn., Dec. 28, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has received a $15 million milestone payment from Janssen Research...
December 05, 2016 16:05 ET | Source: Achillion Pharmaceuticals, Inc.

Data Presented at American Society of Hematology Meeting Demonstrate Potential Advantages of Factor D Inhibition for the Treatment of Complement Alternative Pathway-Mediated Diseases

SAN DIEGO, Dec. 05, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced novel research into complement biology that both expands the understanding of this...
November 30, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Initiation of Patient Dosing by Janssen in a Global, Short Treatment-Duration Phase 2b Study of JNJ-4178 in Chronic HCV

- Janssen initiates dosing of patients in OMEGA-1: Phase 2b study evaluating six- and eight-week treatment durations with JNJ-4178, a 3DAA combination of odalasvir, simeprevir, and AL-335, for the...
November 03, 2016 09:01 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces Upcoming Presentations of Novel Research Into Complement Biology at the 58th Annual Meeting of the American Society of Hematology

NEW HAVEN, Conn., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that two abstracts have been accepted for poster presentation at the...
November 03, 2016 09:00 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Reports Third Quarter 2016 Financial Results And Provides Update On Clinical Programs

Janssen HCV triple combination candidate JNJ-4178 reported 100% SVR12 after 6 weeks of therapy; global phase IIB study to begin 4Q 2016Achillion’s phase I MAD study with oral factor D inhibitor...
November 02, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at the Credit Suisse 25th Annual Healthcare Conference

NEW HAVEN, Conn., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of...
September 23, 2016 11:50 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces 100% SVR12 in the 6-Week and 8-Week Cohorts in Janssen’s Phase 2 Trial Evaluating the Triple Combination Treatment Regimen Including Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naïve HCV

- ePoster presented today at the EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Ongoing Phase 2 development focusing on triple...
September 09, 2016 06:15 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV

- New data released today in abstract for upcoming EASL / AASLD Special Conference: New Perspectives in Hepatitis C Virus Infection – The Roadmap For Cure - - Janssen advancing triple combination...
September 06, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion Presents Novel Research on Factor D Inhibition at the XXVIth International Complement Workshop

NEW HAVEN, Conn., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the presentation of two posters which detailed novel preclinical research into...
September 01, 2016 06:05 ET | Source: Achillion Pharmaceuticals, Inc.

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right